Product Description
Boehringer Ingelheim is developing BI-764532 as a treatment for Patients With Small Cell Lung Carcinoma and Other Neoplasms. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04429087)
Mechanisms of Action: DLL3 Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Large Cell Carcinoma|Neuroendocrine CarcinomaFast Track - Lung Cancer|Small Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Bulgaria, China, France, Germany, Italy, Japan, Korea, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 14
Highest Development Phases
Phase 2: Large Cell Carcinoma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Small Cell Lung Cancer
Phase 1: Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DAREONâ¢-5 | P2 |
Active, not recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer|Neuroendocrine Tumors |
2026-10-30 |
|
| DAREONâ¢-7 | P1 |
Recruiting |
Neuroendocrine Tumors |
2026-07-06 |
|
| jRCT2031230615 | P1 |
Not yet recruiting |
Small Cell Lung Cancer |
2026-06-30 |
|
| NCT05963867 | P1 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer|Neuroendocrine Tumors |
2026-01-18 |